Skip to main content
OpenTrials
Completed

NCT Number: NCT03714646

Beta Glucan and Acetate Production

Based on our hypothesis that orally administered resistant starch and beta glucan will be fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects on human substrate and energy metabolism, we aim to address the following primary objective:

To investigate the effects of an acute administration of inulin/beta glucan in combination with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pre Diabetes Body Weight Glucose Intolerance Glucose Metabolism Disorders Hyperglycemia Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

30 year–65 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Maastricht University

Maastricht, Limburg, 5229 ER, Netherlands

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • lean (BMI ≥ 20kg/m2 and ≤ 24.9kg/m2)
  • normoglycemic
  • aged 30 - 65 years

OR

  • overweight/obese (BMI ≥ 25kg/m2 and ≤ 34.9kg/m2)
  • pre-diabetes
  • aged between 30 - 65 years.

Exclusion criteria

  • diabetes mellitus
  • gastroenterological diseases or major abdominal surgery (allowed i.e.: ---appendectomy, cholecystectomy)
  • lactose intolerance and other digestive disorders
  • cardiovascular disease, cancer, liver or kidney malfunction (determined based on ALAT and creatinine levels, respectively)
  • disease with a life expectancy shorter than 5 years
  • Use of antibiotics 3 months prior inclusion
  • Use of probiotics or prebiotics

Treatment and study plan

beta glucan and resistant starch

Dietary Supplement

12g per day the day before the CID Resistant starch 7.5 g

Placebo

Dietary Supplement

isocaloric maltodextrin before the CID

beta gluten

Dietary Supplement

12 g beta gluten there day before the CID

Primary outcomes

  1. Plasma acetate concentrations (microM)

    Time frame: at baseline (before a high-fat mixed meal)

  2. Plasma acetate concentrations (microM)

    Time frame: four hours after a high fat mixed meal

Secondary outcomes

  1. Energy expenditure (kJ/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)

    Time frame: at baseline and four hours after a high fat mixed meal

  2. fat oxidation (g/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)

    Time frame: at baseline and four hours after a high fat mixed meal

  3. carbohydrate oxidation (g/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)

    Time frame: at baseline and four hours after a high fat mixed meal

  4. Circulating hormone concentrations (Insulin, GLP-1, PYY)

    Time frame: at baseline and four hours after a high fat mixed meal

  5. Circulating metabolite concentrations (Glucose, Free Fatty Acids, Triglycerides)

    Time frame: at baseline and four hours after a high fat mixed meal

  6. Plasma glucose (mmol/L)

    Time frame: at baseline and four hours after a high fat mixed meal

  7. Free Fatty Acids (micromol/L)

    Time frame: at baseline and four hours after a high fat mixed meal

  8. Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)

    Time frame: at baseline and four hours after a high fat mixed meal

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Registry information

Official study title

The Effects of Beta Glucan on Acetate Production and Human Substrate Metabolism

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Oct 22, 2018
Registry last updated
Jan 13, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.